These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8376814)

  • 1. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
    Belshe RB; Anderson EL; Walsh EE
    J Infect Dis; 1993 Oct; 168(4):1024-9. PubMed ID: 8376814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
    Murphy BR; Prince GA; Walsh EE; Kim HW; Parrott RH; Hemming VG; Rodriguez WJ; Chanock RM
    J Clin Microbiol; 1986 Aug; 24(2):197-202. PubMed ID: 3755730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.
    Tristram DA; Welliver RC; Mohar CK; Hogerman DA; Hildreth SW; Paradiso P
    J Infect Dis; 1993 Jan; 167(1):191-5. PubMed ID: 8418166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
    Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
    Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
    Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR
    Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response.
    Akerlind-Stopner B; Utter G; Norrby E; Mufson MA
    J Med Virol; 1995 Oct; 47(2):120-5. PubMed ID: 8830114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.
    Tristram DA; Welliver RC; Hogerman DA; Hildreth SW; Paradiso P
    Vaccine; 1994 May; 12(6):551-6. PubMed ID: 8036830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
    Murphy BR; Walsh EE
    J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine.
    Kakuk TJ; Soike K; Brideau RJ; Zaya RM; Cole SL; Zhang JY; Roberts ED; Wells PA; Wathen MW
    J Infect Dis; 1993 Mar; 167(3):553-61. PubMed ID: 8440926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
    Murphy BR; Prince GA; Collins PL; Hildreth SW; Paradiso PR
    Vaccine; 1991 Mar; 9(3):185-9. PubMed ID: 2042390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity.
    Oien NL; Brideau RJ; Thomsen DR; Homa FL; Wathen MW
    Vaccine; 1993; 11(10):1040-8. PubMed ID: 8212825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
    Levine S; Dillman TR; Montgomery PC
    Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
    J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.